World Immunotherapy Congress - Agenda Day 2

 

World Immunotherapy Congress 2018, Day 2

08:00 Registration Opens

08:50 Conference doors open

Combination therapies

10:10 Networking refreshment break

Oncology – immunotherapy for solid tumours

Manufacture, logistics and supply chain

Chaired by Jonathan Back, Deputy Director, Project Team Lead, Drug Discovery, Glenmark Pharmaceuticals

Chaired by Lothar Germeroth, SVP, Managing Director, Juno Therapeutics GmbH, A Celgene Company

Immunotherapy - Immunotherapy for solid tumours
11:25

Targeting the integrin αvβ6 with CAR T-cells to treat multiple solid malignancies

  • The integrin αvβ6 is overexpressed in multiple solid cancers and is associated with poor prognosis
  • Development of CAR T-cells targeting αvβ6
  • Pre-clinical in vivo models to test CAR T-cell therapeutic approach
Immunotherapy - Manufacture, logistics and supply chain
11:25

Closed systems for CAR T-cell production

  • Closed non-magnetic selection technology (automated T-CATCH)
  • Soluble reversible activation technology (Expamer)
  • Short production process (Nex-T)
Immunotherapy - Immunotherapy for solid tumours
11:45

T-SIGn viruses: systemic delivery of localised combination immuno-gene therapy within the tumour microenvironment

  • T-SIGn platform: transgene-bearing genetically modified variants of enadenotucirev, an oncolytic chimeric group B adenovirus with clinical data demonstrating virus delivery to tumours following systemic dosing
  • Up to 4 different transgenes have been encoded in a single virus, enabling the design of candidates expressing combinations of biological agents for targeted immunotherapy
  • Local production of therapeutic combinations by tumour cells infected with the T-SIGn virus enables high local production for increased activity while minimizing systemic exposure for improved safety
Immunotherapy - Manufacture, logistics and supply chain
11:45

Cell therapy supply chain management, logistics and scale out

  • Shipper suitability, features and options
  • Maintaining chain of custody for starting material and product
  • Logistics reliability and options
  • Supply chain sustainability and scale-out
Immunotherapy - Immunotherapy for solid tumours
12:05

T cell redirecting antibodies based on Glenmark’s BEAT® platform

  • Presentation of GBR 1302 a CD3xHER2 T cell redirecting BEAT antibody currently in clinical development in metastatic breast and gastric cancers
  • Preclinical data highlighting the mechanism of action, and potency, in relation with standard of care
  • Translational data on primary cancer samples in relation with checkpoint combination and immune contexture
Immunotherapy - Manufacture, logistics and supply chain
12:05

Development of endogenous and engineered TCR-T cell therapies for solid cancers

  • Immatics has a proprietary tumor antigen targets discovery platform, XPRESIDENT® which identifies tumor targets and screen TCRs against off-target toxicities
  • Endogenous and engineered TCRs against these tumor targets are used in Immatics’ Adoptive Cellular Therapy programs
  • IMA101 is a multi-product endogenous T cells against a warehouse of targets against various solid cancers currently in phase 1 clinical trial
  • IMA201, 202, and 203 are individual TCR engineered T cell products in various phase 1 trials for various solid cancers
  • Extensive process development was carried out using primary T cells derived from multiple healthy donors and cancer patients to optimize each step in the manufacturing of TCR T cells for 3 clinical trials (IMA101, IMA201, and IMA202)
  • Manufacturing for 3 trials in progress and a 4th is in progress
Immunotherapy - Immunotherapy for solid tumours
12:25

T3 Pharma’s versatile bacterial cancer therapy

  • How to target bacteria to solid tumours
  • How to enable bacteria to fight solid tumours
  • Use of such bacteria in immunotherapy
Immunotherapy - Manufacture, logistics and supply chain
12:25

WORKSHOP: Logistics and supply chain management for cell therapy

  • Developing manufacturing that produces a high-quality product
  • Scalable to meet changing demands of cell therapies
  • Keeping reasonable cost of goods
  • Fully characterising cell therapy products
Immunotherapy - Immunotherapy for solid tumours
12:45

Extended Q&A

Your opportunity to ask the speakers questions!

Networking lunch

Oncology – combination therapy

Chaired by Frédéric Triebel, Chief Scientific Officer, Chief Medical Officer, Immutep Limited

Immunotherapy - Combination therapy
14:35

Expanding immunotherapy by changing the tumour microenvironment

  • MedImmune has a portfolio of therapies aimed at expanding the patient population that will be responsive to immunotherapy Including:
  • Modulating adenosine by CD73 blockade
  • Cytokine expressing Oncolytic virus
Immunotherapy - Combination therapy
14:55

Two ACTive immunotherapies in melanoma (TACTI-mel): results of a phase I trial combining a soluble LAG-3 receptor (Eftilagimod Alpha) with Pembrolizumab

  • Understand the rationale for combining an APC activator (LAG-3lg or “efti”) with an immune checkpoint inhibitor (anti-PD-1 pembrolizumab)
  • Pharmacodynamic effects of efti (6 or 30 mg s.c.) in patients
  • Highlighting in vitro and in vivo preclinical data along with emerging clinical data
Immunotherapy - Combination therapy
15:15

IgA as novel antibody format for lymphoma and neuroblastoma is enhanced by myeloid checkpoint inhibitors

  • IgA recruits neutrophils as effector cells for treatment of cancer
  • Preclinical evidence for mode of action of IgA
  • Adverse effect for neuroblastoma treatment is eliminated with IgA
  • Myeloid checkpoint block strongly enhances IgA effects
Immunotherapy - Combination therapy
15:35

Hexavalent TNFR-SF agonists for cancer Immunotherapy: HERA-CD40L, HERA-CD27L and beyond

  • Understand the structure function relation of the TNFR-SF/TNF-SF interaction and the subsequent design of the HERA-fusion proteins
  • In vitro and in vivo preclinical data illustrating the activity of HERA-based agonists to specifically activate distinct immune cell types involved in the anti-tumor immune reaction
  • Outlook on potential combinations with other IO-drugs

15:55 Networking Break

Oncology - neoantigens

Immunotherapy for non-oncology

Chaired by Agnete Frederiksen, President and Chief Scientific Officer, Vaccibody

Chaired by Ahuva Nissim, Professor, William Harvey Research Institute, Queen Mary University

Immunotherapy - Neoantigens
17:00

Driving high T-cell titers to neoantigens in tumours – harnessing immunogenic viral vectors with immune check point modulators

  • DNA damage may cause mutations in tumours that can generate new antigens, known as tumour-specific neo-antigens (TSNAs)
  • Accurate prediction of TSNAs is key to generate potent TSNA specific vaccine approaches
  • Viral vector based vaccine platforms have shown to induce hi-titer, polyfunctional and durable CD4+ and CD8+ T-cell responses in humans
  • The personalized vaccine is delivered in combination with immune checkpoint blockade, to keep TSNA-induced T-cells active in the immunosuppressive tumour microenvironment
Immunotherapy - Immunotherapy for non-oncology
17:00

Targeting combined treatments to arthritic joints by antibody-specific to damaged cartilage: a safer therapy platform for rheumatoid arthritis

  • There are 40% of patients with rheumatoid arthritis that do not respond to treatments
  • A major issue with systemic treatment due to side effects
  • We developed a platform that can address these unmet needs by:
    • Targeting treatments to the disease tissue
    • Utilize the efficacy of combined biologics which could otherwise lead to major advert effects if administered systemically
Immunotherapy - Neoantigens
17:20

ACE ImmunoID platform for the next generation of cancer immunotherapies and combination clinical trials

  • Current limitations with conventional next generation sequencing assays and Personalis’ solutions to overcome these challenges with its Accuracy and Content Enhanced technology
  • Key considerations for designing rapid, patient-centric processes for neoantigen-based cancer vaccine clinical trials and combination therapies
  • A case study demonstrating the platform’s applicability in identifying multidimensional biomarkers for cancer immunotherapy
Immunotherapy - Immunotherapy for non-oncology
17:20

The promises of low dose IL-2 in autoimmune diseases

  • There is a regulatory T cell (Treg) insufficiency in most autoimmune diseases
  • IL-2 is the main cytokine supporting survival and activation of Tregs, and also block the differentiation of IL-17 and Tfh cells
  • IL-2 has proved efficient in more than 30 experimental models of autoimmune or inflammatory diseases in mice
  • We report “universal” biological and clinical effects of IL-2 in patients with one of 14 different autoimmune diseases treated in the same clinical trial
Immunotherapy - Neoantigens
17:40

Development of a cost-effective personalized cancer neoantigen vaccines inducing a unique CD8-dominated T cell response

  • Potentiating vaccines by attracting, activating and delivering antigens to antigen presenting cells
  • Targeting results in a unique CD8-dominated T cell response.
  • DNA vaccine format allows a rapid, cost-effective and robust manufacturing process viable for manufacturing patient-specific vaccines on demand
  • A clinical study using targeted Vaccibody neoepitope DNA vaccines in multiple advanced cancer indications is ongoing
Immunotherapy - Immunotherapy for non-oncology
17:40

Proteomics crashes at the intersection of autoimmunity and cell biology

  • Review novel protein modifications that trigger autoimmune responses and pathology
  • Discuss proteins modifications that also alter cell biology and metabolism
  • Protein biomarkers as indicators of disease progression and therapeutic strategies
Immunotherapy - Neoantigens
18:00

Individualized therapeutic cancer vaccines – How to select for immunogenic neoantigens?

  • Selecting the right tumour specific antigens - the key for successful therapeutic T cell cancer vaccines
  • Bypassing prediction - identification of tumour specific T cell antigens by a functional readout
  • Vaccination with common tumour antigens - decoding the “Mutanome” presented on HLAs
Immunotherapy - Immunotherapy for non-oncology
18:00

Combinatorial therapeutic HIV-1 vaccines: Time for immune checkpoint inhibitors

  • Talk will focus on HIV-1 infected and treated patients who received therapeutic vaccination
  • Discuss the current work on how to improve therapeutic vaccination using immune checkpoint inhibitors

18:20 Poster presentation and networking drinks

last published: 23/Oct/18 13:25 GMT

 

There are two parts to the Festival of Biologics: the five world-class international conferences covering Antibodies, Immunotherapy, BioSimilars, Clinical Trials, and High Potency APIs; and an exhibition featuring the most exciting technology and solutions for pharma and biotech. There is a registration fee to attend the conferences. To visit the exhibition is free.


Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October 

Sign Up for Event Updates